Intention to Treat Analysis
"Intention to Treat Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Strategy for the analysis of RANDOMIZED CONTROLLED TRIALS AS TOPIC that compares patients in the groups to which they were originally randomly assigned.
| Descriptor ID |
D057194
|
| MeSH Number(s) |
E05.318.760.250.500.365.500.250 N05.715.360.775.088.500.387.500.500 N06.850.520.450.250.250.365.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Intention to Treat Analysis".
Below are MeSH descriptors whose meaning is more specific than "Intention to Treat Analysis".
This graph shows the total number of publications written about "Intention to Treat Analysis" by people in this website by year, and whether "Intention to Treat Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 55 | 56 |
| 2018 | 2 | 35 | 37 |
| 2019 | 0 | 14 | 14 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 9 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Intention to Treat Analysis" by people in Profiles.
-
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. Am J Epidemiol. 2021 11 02; 190(11):2405-2419.
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
-
Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2021 08 02; 4(8):e2121867.
-
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021 09; 9(9):1010-1020.
-
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021 08; 9(8):924-932.
-
Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect. 2021 Oct; 27(10):1494-1501.
-
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021 05; 9(5):498-510.
-
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon ß-1a differed from standard care for in-hospital mortality. Ann Intern Med. 2021 02; 174(2):JC17.
-
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021 05; 235:54-64.
-
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 02 18; 384(7):610-618.